Intended for healthcare professionals


Wegovy: FDA approves weight loss drug to cut cardiovascular risk

BMJ 2024; 384 doi: (Published 13 March 2024) Cite this as: BMJ 2024;384:q642
  1. Janice Hopkins Tanne
  1. New York

The US Food and Drug Administration (FDA) has approved a new use for the injectable weight loss drug Wegovy (semaglutide) to reduce cardiovascular risks such as heart attacks and strokes in adults who have heart disease and are overweight or obese but do not have diabetes.1

The drug, made by Novo Nordisk, should be used with a reduced calorie diet and increased physical activity, FDA said.

Wegovy is one of several popular injectable weight loss drugs. FDA’s approval may increase demands for …

View Full Text

Log in

Log in through your institution


* For online subscription